Newsletter April 2019
In view of the final fundraising phase of our fifth fund, we would like to take the perspective of private equity investors (LPs) in this newsletter. When we discuss the world of private equity investment with LPs, they often express the concern that valuations are currently too high and that holding companies can only acquire companies through price-driving auctions.
Investors who wish to maintain or increase their private equity position are therefore faced with the task of finding providers who a) source their deals using in-depth vertical industry experience from proprietary sources, b) seek true strategic company value increases and c) are not dependent in their exit strategy on selling to the next investor. The latter can lead to considerable valuation losses, especially if interest rates only rise slightly.
Read an informative interview with our colleague André Zimmermann on the subject in this newsletter. He describes how we specifically support our portfolio companies in increasing corporate value and how we primarily aim to sell companies to strategically oriented, multinational medical technology groups.
We also provide examples of cooperations between our portfolio companies and blue-chip groups and institutions, including Boehringer Ingelheim, KUKA and the Mayo Clinic in the US. For many companies, working with industry leaders also leads to a significant increase in company value!
We also have news about the SHS team. Mr. Manfred Ulmer-Weber has been named partner. Congratulations!
I hope you enjoy reading our newsletter!